Evidence map›Paper›PMID 32454714›Full record

ArticleTurkish journal of pharmaceutical sciences2019

Optimization of Thiazolidone Scaffolds Using Pocket Modeling for Development of Potential Secretory System Inhibitors of

Shivratna V Khare, Sujata P Choudhari, Siddharth P Phalle, Santosh S Kumbhar, Prafulla B Choudhari, Sambhaji R Masal, Aakash K Patil, Rakesh P Dhavale, Durgacharan A Bhagwat, Atul M Kadam

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shivratna V KhareBharati Vidyapeeth College of Pharmacy, Department of Pharmaceutical Chemistry, Computational Chemistry Research Lab, Kolhapur, India.
Sujata P ChoudhariSarojini College of Pharmacy, Department of Pharmaceutical Analysis, Kolhapur, India.
Siddharth P PhalleBharati Vidyapeeth College of Pharmacy, Department of Pharmaceutical Chemistry, Computational Chemistry Research Lab, Kolhapur, India.
Santosh S KumbharBharati Vidyapeeth College of Pharmacy, Department of Pharmaceutical Chemistry, Computational Chemistry Research Lab, Kolhapur, India.
Prafulla B ChoudhariBharati Vidyapeeth College of Pharmacy, Department of Pharmaceutical Chemistry, Computational Chemistry Research Lab, Kolhapur, India.ORCID https://orcid.org/0000-0002-9137-3982
Sambhaji R MasalBharati Vidyapeeth College of Pharmacy, Department of Pharmaceutical Chemistry, Computational Chemistry Research Lab, Kolhapur, India.
Aakash K PatilBharati Vidyapeeth College of Pharmacy, Department of Pharmaceutical Chemistry, Computational Chemistry Research Lab, Kolhapur, India.
Rakesh P DhavaleBharati Vidyapeeth College of Pharmacy, Department of Pharmaceutics, Kolhapur, India.
Durgacharan A BhagwatBharati Vidyapeeth College of Pharmacy, Department of Pharmaceutics, Kolhapur, India.
Atul M KadamShree Santkrupa College of Pharmacy, Department of Pharmaceutics, Ghogaon, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesMATERIALS AND

methodsIn the present communication, rational development of an antimycobacterial agent's targeting protein export system was carried out by integrating pocket modeling and virtual analysis.

resultsThe 23 identified potential lead compounds were synthesized, characterized by physicochemical and spectroscopic methods like infrared and nuclear magnetic resonance spectroscopy, and further screened for antimycobacterial activity using isoniazid as standard. All the designed compounds showed profound antimycobacterial activity.

conclusionWe found that Q30, M9, M26, U8, and R26 molecules had significant desirable biological activity and specific interactions with Sec of mycobacteria. Further optimization of these leads is necessary for the development of potential antimycobacterial drug candidates with fewer side effects.

Indexed as

antimycobacterialdockingESXmultidrug resistantMycobacterium tuberculosispocket modelingSec

Identifiers

PMID32454714
PMCPMC7227957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.